SCHEMBL2002174

SCHEMBL2002174

CC(c1ccc(-c2cc(F)cnc2Cl)cc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.38
USP1 O94782 2/20 0.38
TNF P01375 2/20 0.36
PTGES O14684 1/20 0.35
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DHODH Q02127 1/20 0.34
HTR1A P08908 1/20 0.33
CLK1 P49759 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
CREBBP Q92793 1/20 0.33
MET P08581 2/20 0.33
HPGD P15428 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002171 1.00 NR3C2 (0.38) NR3C2USP1TNFPTGESLMNA
SCHEMBL2006367 0.84 TNF (0.38) USP1TNFHPGDNPY1RNPY2R
SCHEMBL2002894 0.75 ADRB2 (0.42) CCNT1CDK9
SCHEMBL2003919 0.75 ADRB2 (0.42) CCNT1CDK9
SCHEMBL4187782 0.73 PIK3CD (0.37) KMT2ASMN1; SMN2METHPGDNPSR1
SCHEMBL12846303 0.73 KMT2A (0.55) TNFPTGESLMNAKMT2A
SCHEMBL12845880 0.73 KMT2A (0.55) TNFPTGESLMNAKMT2A
SCHEMBL5170080 0.71 TNF (0.44) TNFPTGESLMNAKMT2A
SCHEMBL2012134 0.71 LMNA (0.41) USP1TNFLMNAKMT2ASMN1; SMN2
SCHEMBL2012132 0.71 LMNA (0.41) USP1TNFLMNAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960365-B2 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor NR3C1, NR3C2, MC2R NR3C2 2/4885USP1 2619/4885TNF 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.